AstraZeneca, FOB Synthesis to Make Bacterial Infection Antibiotic

AstraZeneca and FOB Synthesis will partner to develop a new antibiotic to treat drug-resistant bacterial infections, by potentially combining AZ’s preclinical beta lactamase inhibitor (BLI) with the synthesis company’s preclinical carbapenem antibiotic, designed to help break down bacteria’s resistance to carbapenems. The companies did not disclose the value of their research and development option and license agreement at this time. Read the full story

More News:

All news »

What are your comments?

Join the discussion today. Login Here.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments